Kingsoft And 2 Top High Growth Tech Stocks In Hong Kong

As global markets face heightened volatility and economic uncertainty, the Hong Kong tech sector remains a focal point for investors seeking high growth opportunities. This article will explore three standout stocks in this space, including Kingsoft, highlighting what makes them compelling choices amid current market conditions.

Top 10 High Growth Tech Companies In Hong Kong

Name	Revenue Growth	Earnings Growth	Growth Rating
Wasion Holdings	22.37%	25.47%	★★★★★☆
MedSci Healthcare Holdings	48.74%	48.78%	★★★★★☆
Inspur Digital Enterprise Technology	25.37%	39.10%	★★★★★☆
Cowell e Holdings	31.82%	35.43%	★★★★★★
Innovent Biologics	21.45%	59.82%	★★★★★☆
RemeGen	26.30%	52.19%	★★★★★☆
Akeso	32.75%	54.99%	★★★★★★
Sichuan Kelun-Biotech Biopharmaceutical	25.22%	9.81%	★★★★★☆
Biocytogen Pharmaceuticals (Beijing)	21.53%	109.17%	★★★★★☆
Beijing Airdoc Technology	37.47%	93.35%	★★★★★☆

Click here to see the full list of 45 stocks from our SEHK High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Kingsoft (SEHK:3888)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kingsoft Corporation Limited engages in the entertainment and office software and services businesses in Mainland China, Hong Kong, and internationally, with a market cap of HK$27.92 billion.

Operations: Kingsoft generates revenue primarily from its Office Software and Services segment (CN¥4.80 billion) and Entertainment Software segment (CN¥4.18 billion). The company's business operations span Mainland China, Hong Kong, and international markets.

Kingsoft's recent earnings report highlights a significant surge, with Q2 revenue reaching ¥2.47 billion, up from ¥2.19 billion last year, and net income jumping to ¥393.35 million from ¥57.19 million previously. The company's focus on software and AI has driven this growth, particularly through its cloud services segment which is increasingly moving to SaaS models for recurring revenue streams. Notably, Kingsoft's R&D expenses reflect a commitment to innovation, with CNY 1 billion invested in the past year alone. Additionally, their share repurchase program aims to enhance shareholder value by buying back up to 10% of issued shares.

• Take a closer look at Kingsoft's potential here in our health report.

• Examine Kingsoft's past performance report to understand how it has performed in the past.

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company involved in the research, development, manufacturing, and commercialization of novel drugs for unmet medical needs in China and internationally, with a market cap of HK$37.21 billion.

Operations: Kelun-Biotech generates revenue primarily from its pharmaceuticals segment, amounting to CN¥1.88 billion. The company focuses on developing and commercializing novel drugs for unmet medical needs both in China and internationally.

Sichuan Kelun-Biotech Biopharmaceutical has shown promising growth, with revenue increasing by 24.7% over the past year and expected to grow at an annual rate of 25.2%. The company’s R&D expenses are significant, reflecting a strong focus on innovation, with CNY 1 billion invested in the past year alone. Recent product announcements include positive results for their anti-TROP2 ADC sacituzumab tirumotecan (sac-TMT) in various cancer treatments, indicating robust potential for future expansion and market penetration.

• Get an in-depth perspective on Sichuan Kelun-Biotech Biopharmaceutical's performance by reading our health report here.

• Learn about Sichuan Kelun-Biotech Biopharmaceutical's historical performance.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that researches, develops, manufactures, and commercializes antibody drugs with a market cap of HK$48.31 billion.

Operations: Akeso focuses on the research, development, production, and sale of biopharmaceutical products, generating CN¥1.87 billion in revenue. The company specializes in antibody drugs within the biopharmaceutical sector.

Akeso's revenue is forecast to grow 32.7% annually, significantly outpacing the Hong Kong market's 7.3%. Despite a net loss of CNY 238.59 million for H1 2024, its innovative R&D efforts are noteworthy, with substantial investment in developing ivonescimab and other bi-specific antibodies. Ivonescimab recently received priority review for new indications and demonstrated superior efficacy in clinical trials compared to pembrolizumab, positioning Akeso as a potential leader in immunotherapy advancements.

• Click here and access our complete health analysis report to understand the dynamics of Akeso.

• Evaluate Akeso's historical performance by accessing our past performance report.

Where To Now?

• Access the full spectrum of 45 SEHK High Growth Tech and AI Stocks by clicking on this link.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com